Literature DB >> 33594424

m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma.

Jianyang Du1,2, Hang Ji1,2, Shuai Ma1, Jiaqi Jin1,2, Shan Mi1,2, Kuiyuan Hou1,2, Jiawei Dong1, Fang Wang1,2, Chaochao Zhang3, Yuan Li4, Shaoshan Hu1.   

Abstract

m6A RNA methylation is an emerging epigenetic modification, and its potential role in immunity and stemness remains unknown. Based on 17 widely recognized m6A regulators, the m6A modification patterns and corresponding characteristics of immune infiltration and stemness of 1152 low-grade glioma samples were comprehensively analyzed. Machine-learning strategies for constructing m6AScores were trained to quantify the m6A modification patterns of individual samples. Here, we reveal a significant correlation between the multi-omics data of regulators and clinicopathological parameters. We identified two distinct m6A modification patterns (an immune-activated differentiation pattern and an immune-desert dedifferentiation pattern) and four regulatory patterns of m6A methylation on immunity and stemness. We show that the m6AScores can predict the molecular subtype of low-grade glioma, the abundance of immune infiltration, the enrichment of signaling pathways, gene variation and prognosis. The concentration of high immunogenicity and clinical benefits in the low-m6AScore group confirmed the sensitive response to radio-chemotherapy and immunotherapy in patients with high-m6AScore. The results of the pan-cancer analyses illustrate the significant correlation between m6AScore and clinical outcome, the burden of neoepitope, immune infiltration and stemness. The assessment of individual tumor m6A modification patterns will guide us in improving treatment strategies and developing objective diagnostic tools.
© The Author(s) 2021. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  immunotherapy; m6A; machine learning; pan-cancer; stemness; tumor immune microenvironment

Year:  2021        PMID: 33594424     DOI: 10.1093/bib/bbab013

Source DB:  PubMed          Journal:  Brief Bioinform        ISSN: 1467-5463            Impact factor:   11.622


  24 in total

1.  Tertiary lymphoid structure patterns predicted anti-PD1 therapeutic responses in gastric cancer.

Authors:  Quan Jiang; Chenyu Tian; Hao Wu; Lingqiang Min; Hao Chen; Lingli Chen; Fenglin Liu; Yihong Sun
Journal:  Chin J Cancer Res       Date:  2022-08-30       Impact factor: 4.026

2.  Palmitoyl transferases act as potential regulators of tumor-infiltrating immune cells and glioma progression.

Authors:  Feng Tang; Chao Yang; Feng-Ping Li; Dong-Hu Yu; Zhi-Yong Pan; Ze-Fen Wang; Zhi-Qiang Li
Journal:  Mol Ther Nucleic Acids       Date:  2022-05-04       Impact factor: 10.183

3.  Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas.

Authors:  Wangrui Liu; Chuanyu Li; Yuhao Wu; Wenhao Xu; Shuxian Chen; Hailiang Zhang; Haineng Huang; Shuai Zhao; Jian Wang
Journal:  Front Cell Dev Biol       Date:  2021-11-25

4.  m6A Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes.

Authors:  Jiawei Chen; Shuchen Sun; Leihao Ren; Lingyang Hua; Daijun Wang; Qing Xie; Hans-Georg Wirsching; Jiaojiao Deng; Michael Weller; Ye Gong
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

5.  The Non-N6-Methyladenosine Epitranscriptome Patterns and Characteristics of Tumor Microenvironment Infiltration and Mesenchymal Transition in Glioblastoma.

Authors:  Jianye Xu; Zijie Gao; Kaining Liu; Yang Fan; Zongpu Zhang; Hao Xue; Xing Guo; Ping Zhang; Lin Deng; Shaobo Wang; Huizhi Wang; Qingtong Wang; Rongrong Zhao; Gang Li
Journal:  Front Immunol       Date:  2022-01-26       Impact factor: 7.561

6.  Cross-Talk Between m6A- and m5C-Related lncRNAs to Construct a Novel Signature and Predict the Immune Landscape of Colorectal Cancer Patients.

Authors:  Wei Song; Jun Ren; Rensheng Xiang; Wenzheng Yuan; Tao Fu
Journal:  Front Immunol       Date:  2022-03-08       Impact factor: 7.561

7.  Prognostic and Immunological Role of mRNA ac4C Regulator NAT10 in Pan-Cancer: New Territory for Cancer Research?

Authors:  Chuanxi Yang; Tingting Wu; Jing Zhang; Jinhui Liu; Kun Zhao; Wei Sun; Xin Zhou; Xiangqing Kong; Jing Shi
Journal:  Front Oncol       Date:  2021-05-19       Impact factor: 6.244

8.  N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.

Authors:  Wei Song; Jun Ren; Wenzheng Yuan; Rensheng Xiang; Yuhang Ge; Tao Fu
Journal:  Genes (Basel)       Date:  2021-08-31       Impact factor: 4.096

Review 9.  N6-Methyladenosine RNA Modification in the Tumor Immune Microenvironment: Novel Implications for Immunotherapy.

Authors:  Liting Guo; Hui Yang; Chenfei Zhou; Yan Shi; Lei Huang; Jun Zhang
Journal:  Front Immunol       Date:  2021-12-09       Impact factor: 7.561

10.  Human Mitochondrial Ribosomal RNA Modification-Based Classification Contributes to Discriminate the Prognosis and Immunotherapy Response of Glioma Patients.

Authors:  Peng Wang; Jingying Li; Miaojing Wu; Minghua Ye; Kai Huang; Xingen Zhu
Journal:  Front Immunol       Date:  2021-09-09       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.